VEGF/ANG2 Tetravalent Bispecific Antibody for Intravitreal Injection


Ocular fundus neovascular diseases, such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME)

Product Advantage

Achieving stronger effectiveness and lower dosing frequency compared with existing anti-VEGF drugs


Class 1 Innovative Biological Product; substance PCT patent application pending

Product Introduction

VEGF+ANG2 Tetravalent Bispecific Antibody is a Class 1 Innovative Biological Product with a unique nanobody design for treatment of ocular fundus neovascular diseases, targeting VEGF (vascular endothelial growth factor) and ANG2 (angiopoietin 2), which effectively inhibits abnormal neovascularization through two different pathways. The Product enjoys the advantages of high affinity, strong inhibitory activity, high preparation concentration, good stability and low dosing frequency. It can reduce the potential risks caused by frequent intravitreal injections that occur to the patients and improve medication compliance of patients, possessing important clinical implications.